Hims & Hers Target Held at $23 by BofA BofA kept Hims & Hers' price target at $23 on Mar 26, 2026; the move underscores continued scrutiny of ARPU and CAC despite sector growth projections (Investing.com).

Hims & Hers Target Held at $23 by BofA: BofA kept Hims & Hers' price target at $23 on Mar 26, 2026; the move underscores continued scrutiny of ARPU and CAC despite sector growth projections (Investing.com). 👈 Read full analysis #HimsAndHers #BOFA #PriceTarget #InvestmentInsights #ARPU

Hims & Hers and Novo Nordisk have resolved their legal dispute and entered a collaboration, with Hims & Hers agreeing to offer Novo's branded GLP-1 drugs — Ozempic and Wegovy — starting later in March while ceasing to market compounded GLP-1 alternatives.

#HIMS #NVO #HimsAndHers #Ozempic #Wegovy

Months of legal wrangling between #NovoNordisk and telehealth company #HimsandHers has been set aside, as the two companies agree to work together once again on the sale of #GLP1agonists for #weightloss.

pharmaphorum.com/news/novo-pa...

Aandelen Hims & Hers stijgen met 50 procent na intrekking rechtszaak door Novo Nordisk Key takeaways Farmaceutgigant Novo Nordisk heeft haar rechtszaak tegen telezorgaanbieder Hims & Hers laten vallen. Volgens Nordisk verkocht Hims & Hers goedkopere- en niet-goedgekeurde kopieën van het populaire afslankmiddel Wegovy. Na overleg hebben de twee bedrijven een overeenkomst gesloten. Hims & Hers zal vanaf nu de medicijnen van Novo Nordisk op haar platform verkopen. Als […]

Aandelen Hims & Hers stijgen met 50 procent na intrekking rechtszaak door Novo Nordisk #HimsAndHers #NovoNordisk #Aandelen #Gezondheid #Telezorg

Hims & Hers Health has agreed to acquire Eucalyptus, Australia's largest digital health provider, in a cash-and-stock deal worth up to $1.15 billion, expected to close in mid-2026.

#HIMS #HIMSStock #HimsAndHers #HimsAndHersStock #Eucalyptus

Hims & Hers buys Australian digital health firm for $1.15bn Hims & Hers, facing a threat to its compounded medicines business, has ramped up its push for international expansion by buying Eucalyptus Health.

Facing the legal consequences of its aborted entry into the #oralGLP1 category in the #US, #telehealth company #HimsandHers has turned its attention to international matters with an agreement to buy #Australian rival #EucalyptusHealth.

Novo Nordisk claims Hims & Hers’ Ozempic and Wegovy alternatives are unsafe and unapproved.

Hims & Hers says it’s about keeping meds affordable.

Is this lawsuit about patient safety or market control?
#Pharma #Ozempic #Wegovy #HimsandHers

Novo Nordisk klaagt Hims & Hers aan wegens kopieën van Wegovy Key takeaways Farmaceutische gigant Novo Nordisk onderneemt juridische stappen tegen Hims & Hers, een online aanbieder van telegezondheidszorg. Hims & Hers zou goedkopere en niet-goedgekeurde kopieën van het populaire afslankmedicijn Wegovy op de markt brengen. “Dit is een complete schijnvertoning”, vertelt John Kuckelman, Novo’s algemeen juridisch adviseur in een interview met CNBC. “Hun medicijnen zijn […]

Novo Nordisk klaagt Hims & Hers aan wegens kopieën van Wegovy #NovoNordisk #HimsAndHers #Wegovy #gezondheidszorg #farmaceutisch

Hims & Hers shrinks....its own stock To quote Ron Burgundy, that escalated quickly. Let's begin with the saga of Hims & Hers and the $49 (introductory) weight-loss pill that was released with great fanfare on Thursday (see Amina N.

Back with another edition of The Business of America, talking #himsandhers and #weightloss and well, #salad.

www.linkedin.com/pulse/hims-h...

📈 US stocks rebounded.
🇪🇺 Europe closed higher amid volatility.
🇯🇵 Nikkei hit record high.
🚀 Kroger soared on new CEO; Hims & Hers fell.
#Markets #US #Europe #Japan #Kroger #HimsAndHers
#Markets #US #Europe #Japan #Kroger #HimsAndHers
View in Timelines

Novo Nordisk rises as Hims & Hers backs down on oral GLP-1 Novo Nordisk's battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the new Wegovy pill.

#NovoNordisk's battered stock enjoyed a moment of reprieve after #HimsandHers abandoned plans to launch a #compoundedversion of the just-launched #Wegovy pill.

pharmaphorum.com/news/novo-no...

Hims & Hers pulls copycat weight-loss pill after threats of legal action
#HimsAndHers #WeightLossPills #HealthcareNews
www.youtube.com/watch?v=4MqJ...

Super Bowl spot will promote a cancer test that can produce false results The telehealth firm is running an ad during Sunday’s game pitching its platform as a way to access health services enjoyed by the wealthy, such as a controversial test to detect cancer with a simple b...

Experts warn these tests miss many cancers, giving patients a dangerous false sense of security.

Or, they may tell you that you have cancer when you don't, leading to expensive, stressful, and sometimes risky tests.

#SuperBowl #HimsAndHers #CancerTest

www.washingtonpost.com/health/2026/...

Hims & Hers copies Novo Nordisk's new Wegovy pill Competition has already arrived for Novo Nordisk's Wegovy pill, as telehealth company Hims & Hers launches a compounded version

Competition has already arrived for Novo Nordisk's #Wegovy pill, as #telehealth company Hims & Hers launches a compounded version. #GLP1 #ObesityDrugs #WeightLossMedication #HimsAndHers #HealthNews #pharma
pharmaphorum.com/news/hims-he...

Grail multi-cancer test taps into Hims & Hers network Grail has teamed up with telehealth company Hims & Hers to boost access to its recently filed Galleri blood test for cancer screening

#Grail has teamed up with #telehealth company #HimsAndHers to boost access to its recently filed #Galleri blood test for multi-cancer screening. #MultiCancerEarlyDetection #CancerScreening #oncology #DigitalHealth #pharmanews pharmaphorum.com/news/grail-m...

In the U.K., eligible customers—following a detailed clinical assessment by GMC-registered doctors—can access transparent pricing and personalized weight-management plans

#HIMS #HIMSStock #HIMSNews #HimsAndHers #HimsAndHersStock #HimsAndHersNews #HimsAndHersCanada #HimsAndHersUK #HIMSCanada
$HIMS

Hims & Hers launches weight-loss business in UK Hims & Hers has launched its direct-to-consumer weight-loss therapy channel in the UK, offering Wegovy, Mounjaro, and OTC option Orlos.

#Telehealth company #HimsandHers has launched its #directtoconsumer #weightloss therapy channel in the #UK, offering #GLP1agonists like Novo Nordisk's Wegovy at a starting price of £149 per month.

Hims & Hers Health announced the launch of Labs, a new preventative-care product that uses blood-test insights to support cardiovascular, metabolic, and overall health

#HIMS #HIMSStock #HIMSNews #HIMSStockNews #HimsAndHers #PreventiveHealth #HealthTech #Telehealth #Wellness #MetabolicHealth
$HIMS

Hims & Hers is in active talks with Novo Nordisk to offer Wegovy injections and, once approved, oral Wegovy

#HIMS #HIMSStock #HIMSNews #HIMSStockNews #HimsAndHers #Wegovy #NovoNordisk #GLP1 #Semaglutide #HealthcareTech #Telehealth #Longevity #GRAIL #Biotech #DigitalHealth #WellnessTech #HIMSEarning

Hims & Hers Health has launched new, affordable treatment options for individuals experiencing perimenopause and menopause, expanding its offerings into hormone-replacement therapies

#HIMS #HIMSStock #HIMSNews #HIMSStockNews #HimsAndHers #Healthcare #Menopause #Perimenopause #HormoneTherapy

Click Subscribe #HimsAndHers #StockMarket #Investing #FinancialNews #FTCInvestigation

Hims & Hers, ThredUp, MercadoLibre: After-hours trending stocks - Yahoo Finance Hims & Hers, ThredUp, MercadoLibre: After-hours trending stocks  Yahoo Finance

Click Subscribe #TrendingStocks #HimsAndHers #ThredUp #MercadoLibre #FinanceNews

Earnings live: Palantir stock pops on raised outlook, Hims & Hers tumbles - Yahoo Finance Earnings live: Palantir stock pops on raised outlook, Hims & Hers tumbles  Yahoo Finance

Click Subscribe #EarningsReport #Palantir #StockMarket #HimsAndHers #Investing

Hims & Hers Health shares dropped after over 80 U.S. lawmakers urged the FDA to take action against compounded and knockoff versions of popular weight loss drugs like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy.

#HIMS #LLY #NVO #HIMSStock #HIMSNews #HIMSStockNews #HimsAndHers
$HIMS $LLY $NVO

Hims & Hers Stock Financial Analysis Following Huge Stock Price Crash - Nasdaq Hims & Hers Stock Financial Analysis Following Huge Stock Price Crash  Nasdaq

Click Subscribe #HimsAndHers #StockMarket #FinancialAnalysis #Investing #StockPrice

Hims & Hers appoints former Robinhood exec Dheerja Kaur as first CPO Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #HimsAndHers #DheerjaKaur #CPO #ProductLeadership #Robinhood

Hims & Hers Dropped by Novo Amid Patient Safety and Compliance Fears

#HIMS #HIMSStock #HIMSNews #HIMSStockNews #NVO #NVOStock #NVONews #NVOStockNews #Wegovy #Semaglutide #HimsAndHers #NovoNordisk #GLP1 #NovoNordiskStock #HimsAndHersStock
$HIMS $NVO

Novo Nordisk ends Wegovy partnership with Hims & Hers over compliance Investing.com - Deutsche Bank maintained its Hold rating and $43.00 price target on Hims & Hers (NYSE:HIMS) stock following Novo Nordisk (NYSE:NVO)’s termination of their partnership. Novo Nordisk announced Tuesday that it would halt its collaboration with Hims & Hers, ending direct access to Wegovy through NovoCare. The Danish pharmaceutical company cited regulatory non-compliance and brand protection concerns as primary reasons for the split, specifically pointing to Hims & Hers’ marketing practices and continued sales of personalized dosages of compounded Wegovy. The termination comes as part of Novo Nordisk’s broader efforts to restrict the use of unapproved alternatives to its weight loss medication. News agencies reported that litigation could potentially resume now that the partnership has ended. Hims & Hers CEO Andrew Dudum responded to the announcement, claiming Novo’s commercial team had increasingly pressured the company regarding clinical standards and pushed patients toward Wegovy regardless of whether it was clinically optimal for them. Hims & Hers stock dropped approximately 33% intraday Tuesday, erasing the 23% gain it had achieved when the partnership was initially announced. The termination marks the end of a month-old relationship that had initially appeared promising for the telehealth company. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Unsure where to invest next? Get access to our proven portfolios and discover high-potential opportunities. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech stocks, and Mid Cap stocks, you can explore various wealth-building strategies.

Click Subscribe #NovoNordisk #Wegovy #HimsAndHers #pharmaceuticals #stockmarket

Novo Nordisk's fling with Hims & Hers ends in a bust-up The alliance between Novo Nordisk and telehealth firm Hims & Hers for the distribution of GLP-1 agonist weight-loss therapies has ended in acrimony.

The alliance between #NovoNordisk and telehealth company #HimsandHers for the distribution of #GLP1 agonist weight-loss therapies has ended in acrimony.

Top Stock Movers Now: Tesla, Hims & Hers, Wolfspeed, and More - Investopedia Top Stock Movers Now: Tesla, Hims & Hers, Wolfspeed, and More  Investopedia

Click Subscribe #StockMarket #Tesla #Investing #HimsAndHers #Wolfspeed